Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), GeneDx Holdings (WGS) and Masimo (MASI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), GeneDx Holdings (WGS – Research Report) and Masimo (MASI – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharma (ALNY)
In a report issued on January 8, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma, with a price target of $500.00. The company’s shares closed last Monday at $370.91.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $501.42, which is a 32.7% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $529.00 price target.
See the top stocks recommended by analysts >>
GeneDx Holdings (WGS)
Craig-Hallum analyst William Bonello maintained a Buy rating on GeneDx Holdings yesterday. The company’s shares closed last Monday at $119.24.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
GeneDx Holdings has an analyst consensus of Strong Buy, with a price target consensus of $171.43, representing a 31.9% upside. In a report issued on January 2, BTIG also maintained a Buy rating on the stock with a $200.00 price target.
Masimo (MASI)
In a report released yesterday, Michael Matson from Needham maintained a Hold rating on Masimo. The company’s shares closed last Monday at $132.23.
According to TipRanks.com, Matson is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $188.40 average price target.
